BMO Capital analyst Gary Nachman raised his price target on Endo to $16 after a “very solid beat and raise” Q2 report, saying he also anticipates potential upside to the company’s guidance for ROY. Nachman notes he was most impressed with the performance of the company’s key growth drivers while its legacy generics stabilized. The analyst keeps his Market Perform rating on Endo given its valuation, high leverage, and modest growth outlook.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.